The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Fluorodeoxiglucose (FDG)-avidity at positron emission computed tomography/computed tomography (PET/CT) during adjuvant hormone therapy (HT) in patients (pts) with breast cancer (BC).
S. Redana
No relevant relationships to disclose
A. Gucalp
No relevant relationships to disclose
C. Ghiotto
No relevant relationships to disclose
L. Vinante
No relevant relationships to disclose
G. Zago
No relevant relationships to disclose
M. N. Fornier
No relevant relationships to disclose
L. Evangelista
No relevant relationships to disclose